Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2016

01-12-2016 | Review

The roles of microRNAs related with progression and metastasis in human cancers

Authors: Hai-Ting Liu, Peng Gao

Published in: Tumor Biology | Issue 12/2016

Login to get access

Abstract

Metastasis is an important factor in predicting the prognosis of the patients with cancers and contributes to high cancer-related mortality. Recent studies indicated that microRNAs (miRNAs) played a functional role in the initiation and progression of human malignancies. MicroRNAs are small non-coding RNAs of about 22 nucleotides in length that can induce messenger RNA (mRNA) degradation or repress mRNA translation by binding to the 3′ untranslated region (3′-UTR) of their target genes. Overwhelming reports indicated that miRNAs could regulate cancer invasion and metastasis via epithelial-to-mesenchymal transition (EMT)-related and/or non-EMT-related mechanisms. In this review, we concentrate on the underlying mechanisms of miRNAs in regulating cancer progression and metastasis.
Literature
1.
Le XF, Merchant O, Bast RC, Calin GA. The roles of microRNAs in the cancer invasion-metastasis cascade. Cancer microenvironment : official journal of the International Cancer Microenvironment Society. 2010;3(1):137–47. doi:10.​1007/​s12307-010-0037-4.CrossRef
2.
3.
Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR. Microenvironmental influences on metastasis suppressor expression and function during a metastatic cell’s journey. Cancer microenvironment : official journal of the International Cancer Microenvironment Society. 2014;7(3):117–31. doi:10.​1007/​s12307-014-0148-4.CrossRef
4.
5.
6.
He W, He S, Wang Z, Shen H, Fang W, Zhang Y, et al. Astrocyte elevated gene-1 (AEG-1) induces epithelial-mesenchymal transition in lung cancer through activating Wnt/beta-catenin signaling. BMC Cancer. 2015;15(1):1124. doi:10.​1186/​s12885-015-1124-1.
7.
8.
9.
10.
Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, et al. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. J Surg Oncol. 2012;105(7):655–61. doi:10.​1002/​jso.​23020.PubMedCrossRef
11.
12.
13.
14.
15.
Sun Y, Huang J, Yang Z. The roles of ADAMTS in angiogenesis and cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi:10.​1007/​s13277-015-3461-8.
16.
Tille JC, Nisato R, Pepper MS. Lymphangiogenesis and tumour metastasis. Novartis Found Symp. 2004;256:112–31 discussion 32-6, 259-69.PubMedCrossRef
17.
18.
19.
20.
Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15(2):180–91.PubMedPubMedCentralCrossRef
21.
22.
23.
Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, et al. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene. 2014. doi:10.​1038/​onc.​2014.​408.PubMedPubMedCentral
24.
25.
Iwai S, Yonekawa A, Harada C, Hamada M, Katagiri W, Nakazawa M, et al. Involvement of the wnt-beta-catenin pathway in invasion and migration of oral squamous carcinoma cells. Int J Oncol. 2010;37(5):1095–103.PubMedCrossRef
26.
Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, et al. A new member of the Frizzled family from Drosophila functions as a wingless receptor. Nature. 1996;382(6588):225–30. doi:10.​1038/​382225a0.PubMedCrossRef
27.
28.
29.
Fu Y, Zheng S, An N, Athanasopoulos T, Popplewell L, Liang A, et al. Beta-catenin as a potential key target for tumor suppression. Int J Cancer J Int du Cancer. 2011;129(7):1541–51. doi:10.​1002/​ijc.​26102.CrossRef
30.
31.
32.
33.
34.
Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, et al. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/beta-catenin signaling. J Clin Endocrinol Metab. 2013;98(8):E1305–13. doi:10.​1210/​jc.​2012-3602.PubMedCrossRef
35.
36.
37.
38.
Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96. doi:10.​1038/​nrm3330.PubMed
39.
Jiang H, Gao M, Shen Z, Luo B, Li R, Jiang X, et al. Blocking PI3K/Akt signaling attenuates metastasis of nasopharyngeal carcinoma cells through induction of mesenchymal-epithelial reverting transition. Oncol Rep. 2014;32(2):559–66. doi:10.​3892/​or.​2014.​3220.PubMed
40.
Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14(5):381–95.PubMedCrossRef
41.
42.
Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, et al. MicroRNA-93 activates c-met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015;6(5):3211–24.PubMedCrossRef
43.
Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis. 2013;34(2):454–63. doi:10.​1093/​carcin/​bgs346.PubMedCrossRef
44.
45.
Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221–4.PubMedCrossRef
46.
47.
48.
49.
Cimino D, De Pitta C, Orso F, Zampini M, Casara S, Penna E, et al. miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J: Off Publ Fed Am Soc Exp Biol. 2013;27(3):1223–35. doi:10.​1096/​fj.​12-214692.CrossRef
50.
Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012;55(6):1852–62. doi:10.​1002/​hep.​25576.PubMedCrossRef
51.
Zhong M, Bian Z, miR- WZ. 30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Biochem: Int J Exp Cell Physiol, Biochem Pharmacol. 2013;31(2–3):209–18. doi:10.​1159/​000343362.
52.
Cui F, Li X, Zhu X, Huang L, Huang Y, Mao C, et al. MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta. Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol. 2012;30(5):1310–8. doi:10.​1159/​000343320.CrossRef
53.
Shi Y, Chen C, Zhang X, Liu Q, Xu JL, Zhang HR, et al. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2014;20(7):1803–13. doi:10.​1158/​1078-0432.​CCR-13-2284.CrossRef
54.
Que T, Song Y, Liu Z, Zheng S, Long H, Li Z, et al. Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1. Oncogene. 2015. doi:10.​1038/​onc.​2014.​419.PubMed
55.
Yu SH, Zhang CL, Dong FS, Zhang YM. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem. 2015;116(2):268–76. doi:10.​1002/​jcb.​24965.PubMedCrossRef
56.
Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG, Sun BM. MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol. 2012;25(4):871–81.PubMedCrossRef
57.
58.
59.
Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W, et al. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget. 2014;5(13):5113–24.PubMedPubMedCentralCrossRef
60.
61.
Zhao HJ, Ren LL, Wang ZH, Sun TT, YN Y, Wang YC, et al. MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. Theranostics. 2014;(12):1193–208. doi:10.​7150/​thno.​8712.
62.
63.
64.
65.
66.
67.
Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008;112(9):2088–100. doi:10.​1002/​cncr.​23410.PubMedCrossRef
68.
69.
70.
Sun V, Zhou WB, Nosrati M, Majid S, Thummala S, de Semir D, et al. Antitumor activity of miR-1280 in melanoma by regulation of Src. Mol Ther: J Am Soc Gene Ther. 2015;23(1):71–8. doi:10.​1038/​mt.​2014.​176.CrossRef
71.
Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res: Off J Am Assoc Cancer Res. 2000;6(6):2417–23.
72.
Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, Cance WG, et al. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(11):3299–305. doi:10.​1158/​1078-0432.​CCR-07-1511.CrossRef
73.
Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996;3(1):100–5.PubMedCrossRef
74.
Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, et al. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget. 2015;6(7):4757–72.PubMedPubMedCentralCrossRef
75.
Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG. MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anti Cancer Agents Med Chem. 2014;14(1):18–28.CrossRef
76.
Wu DG, Wang YY, Fan LG, Luo H, Han B, Sun LH, et al. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J. 2011;124(17):2616–21.PubMed
77.
78.
Hao Z, Yang J, Wang C, Li Y, Zhang Y, Dong X, et al. MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer. Int J Clin Exp Med. 2015;8(1):480–7.PubMedPubMedCentral
79.
80.
81.
82.
83.
84.
Pellegrino L, Krell J, Roca-Alonso L, Stebbing J, Castellano L. MicroRNA-23b regulates cellular architecture and impairs motogenic and invasive phenotypes during cancer progression. BioArchitecture. 2013;3(4):119–24.PubMedPubMedCentralCrossRef
85.
Wang F, Chan LW, Law HK, Cho WC, Tang P, Yu J, et al. Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases. Genomics. 2014;104(6 Pt B):504–11. doi:10.​1016/​j.​ygeno.​2014.​09.​004.PubMedCrossRef
86.
87.
88.
89.
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012;27(6):1967–75. doi:10.​3892/​or.​2012.​1711.PubMed
90.
Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 2014;31(4):1715–22. doi:10.​3892/​or.​2014.​3052.PubMed
91.
92.
93.
94.
Shang C, Lu YM, Meng LR. MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit: Int Med J Exp Clin Res. 2012;18(4):BR149–55.CrossRef
95.
96.
97.
98.
99.
100.
101.
Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori GA. Causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392(6672):190–3. doi:10.​1038/​32433.PubMedCrossRef
102.
Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature reviews. Cancer. 2007;7(6):415–28. doi:10.​1038/​nrc2131.PubMed
103.
104.
105.
Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68(19):7846–54. doi:10.​1158/​0008-5472.​CAN-08-1942.PubMedCrossRef
106.
107.
108.
Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2013;104(1):48–54. doi:10.​1111/​cas.​12030.PubMedCrossRef
109.
110.
111.
Xu Q, Sun Q, Zhang J, Yu J, Chen W, Zhang Z. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis. 2013;34(3):539–49. doi:10.​1093/​carcin/​bgs374.PubMedCrossRef
112.
113.
114.
115.
116.
Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, et al. MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J Orthop Res: Off Publ Orthopaedic Res Soc. 2014;32(8):1075–82. doi:10.​1002/​jor.​22632.CrossRef
117.
118.
Li W, Jiang G, Zhou J, Wang H, Gong Z, Zhang Z, et al. Down-regulation of miR-140 induces EMT and promotes invasion by targeting slug in esophageal cancer. Cell Physiol Biochem: Int J Exp Cell Physiol, Biochem Pharmacol. 2014;34(5):1466–76. doi:10.​1159/​000366351.CrossRef
119.
Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, et al. miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells. Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol. 2013;32(5):1331–41. doi:10.​1159/​000354531.CrossRef
120.
121.
122.
123.
Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting Twist1 in invasive endometrial cancer cell lines. Mol Carcinog. 2014;53(5):349–59. doi:10.​1002/​mc.​21983.PubMedCrossRef
124.
125.
126.
Hernandez JM, Elahi A, Clark CW, Wang J, Humphries LA, Centeno B, et al. miR-675 mediates downregulation of Twist1 and Rb in AFP-secreting hepatocellular carcinoma. Ann Surg Oncol. 2013;20(Suppl 3):S625–35. doi:10.​1245/​s10434-013-3106-3.PubMedCrossRef
127.
128.
129.
Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(4):2041–51. doi:10.​1007/​s13277-013-0842-8.CrossRef
130.
131.
Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H, et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genom Proteomics. 2009;6(3):131–9.
132.
133.
Chen Q, Zhao X, Zhang H, Yuan H, Zhu M, Sun Q, et al. MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2. Mol Carcinog. 2014. doi:10.​1002/​mc.​22204.
134.
135.
Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology. 2011;54(5):1729–40. doi:10.​1002/​hep.​24577.PubMedCrossRef
136.
Tang R, Cui ZM, Lou YH. MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro. Zhonghua fu chan ke za zhi. 2012;47(11):846–50.PubMed
137.
Jin J, Cai L, Liu ZM, Zhou XS. miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev: APJCP. 2013;14(6):3681–4.PubMedCrossRef
138.
139.
Wang W, Lin H, Zhou L, Zhu Q, Gao S, Xie H, et al. MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40(11):1586–94. doi:10.​1016/​j.​ejso.​2013.​11.​008.CrossRef
140.
Zhao ZG, Jin JY, Zhang AM, Zhang LP, Wang XX, Sun JG, et al. MicroRNA profile of tumorigenic cells during carcinogenesis of lung adenocarcinoma. J Cell Biochem. 2015;116(3):458–66. doi:10.​1002/​jcb.​24999.PubMedCrossRef
141.
Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem et Cytobiol/Pol Acad Sci Pol Histochem Cytochemical Soc. 2012;50(1):12–9. doi:10.​2478/​18691.CrossRef
142.
Zhou Y, Li Y, Ye J, Jiang R, Yan H, Yang X, et al. MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver international : official journal of the International Association for the Study of the Liver. 2013;33(8):1271–80. doi:10.​1111/​liv.​12190.CrossRef
143.
144.
Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(9):8653–8. doi:10.​1007/​s13277-014-2131-6.CrossRef
145.
146.
Liu P, Wilson MJ. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-kappaB factor in human fibrosarcoma cells. J Cell Physiol. 2012;227(2):867–76. doi:10.​1002/​jcp.​22993.PubMedPubMedCentralCrossRef
147.
Wu D, Li M, Wang L, Zhou Y, Zhou J, Pan H, et al. microRNA145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma. Mol Med Rep. 2014;10(1):393–8. doi:10.​3892/​mmr.​2014.​2149.PubMed
148.
149.
Siragam V, Rutnam ZJ, Yang W, Fang L, Luo L, Yang X, et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget. 2012;3(11):1370–85.PubMedPubMedCentralCrossRef
150.
151.
152.
153.
154.
155.
156.
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li Z, et al. miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer. Oncotarget. 2015;6(3):1605–17.PubMedPubMedCentralCrossRef
157.
Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, et al. MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget. 2015;6(1):471–83.PubMed
158.
159.
Zheng Y, Li S, Ding Y, Wang Q, Luo H, Shi Q, et al. The role of miR-18a in gastric cancer angiogenesis. Hepato-Gastroenterology. 2013;60(127):1809–13.PubMed
160.
161.
Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 2014;59(5):1874–85. doi:10.​1002/​hep.​26941.PubMedCrossRef
162.
163.
Zhu K, Pan Q, Zhang X, Kong LQ, Fan J, Dai Z, et al. MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis. 2013;34(9):2071–9. doi:10.​1093/​carcin/​bgt160.PubMedCrossRef
164.
165.
166.
167.
168.
Hu J, Cheng Y, Li Y, Jin Z, Pan Y, Liu G, et al. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. Eur J Cancer. 2014;50(13):2336–50. doi:10.​1016/​j.​ejca.​2014.​06.​005.PubMedCrossRef
169.
Jiang L, Wang Y, Rong Y, Xu L, Chu Y, Zhang Y, et al. miR-1179 promotes cell invasion through SLIT2/ROBO1 axis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):319–27.PubMedPubMedCentral
170.
171.
Liu T, Zhang X, Sha K, Liu X, Zhang L, Wang B. miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5. Cell Prolif. 2015. doi:10.​1111/​cpr.​12181.
172.
Chen B, Hou Z, Li C, Tong Y. MiRNA-494 inhibits metastasis of cervical cancer through Pttg1. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2015. doi:10.​1007/​s13277-015-3440-0.
173.
Yang X, Zang W, Xuan X, Wang Z, Liu Z, Wang J, et al. miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma. Int J Oncol. 2015;46(5):2163–71. doi:10.​3892/​ijo.​2015.​2900.PubMed
Metadata
Title
The roles of microRNAs related with progression and metastasis in human cancers
Authors
Hai-Ting Liu
Peng Gao
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5436-9

Other articles of this Issue 12/2016

Tumor Biology 12/2016 Go to the issue

Retraction Note

Retraction Note to: Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study

Original Article

Hedgehog/Gli1 signal pathway facilitates proliferation, invasion, and migration of cutaneous SCC through regulating VEGF

Original article

RETRACTED ARTICLE: Upregulation of miR-20a and miR-10a expression levels act as potential biomarkers of aggressive progression and poor prognosis in cervical cancer

Original Article

Sonic hedgehog signaling pathway mediates development of hepatocellular carcinoma

Original Article

Prognostic risk factors in patients with bone metastasis from colorectal cancer

Original Article

A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits